Biliary Stricture, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma, Perihilar, Diagnosis, Endoscopy, Klatskin Tumor, Malignant Biliary Stricture, Raman Spectroscopy
Conditions
Brief summary
Diagnosis of extrahepatic cholangiocarcinoma is challenging because the yield of imaging and tissue sampling is limited. Raman spectroscopy is an optical method based on the analysis of scattered monochromatic light. Raman spectroscopy is able to provide a molecular 'fingerprint' of the tissue to determine its type. The aim of this pilot study was to develop a methodology for in vivo Raman spectroscopy in bile ducts to improve the current diagnostic capabilities of extrahepatic cholangiocarcinoma.
Detailed description
During ERCP, a fibre Raman probe (Endoscopic Fiber-Optic Raman Probe Bundle Fiber, Uni-Export Instruments, USA) is introduced transpapillary into the known extrahepatic cholangiocarcinoma. The Raman probe is placed in an adequate position under fluoroscopy control. Raman spectroscopy measurements are performed (without fluoroscopy) 20 times for each patient (laser wavelength 785 nm), 10 times for extrahepatic cholangiocarcinoma and 10 times for healthy bile duct. The attained data are saved and analysed by a specialised biophysicist. All patients provided informed consent.
Interventions
PROCEDUREEndoscopic retrograde cholangiopancreatography (ERCP)
Insertion of a endoscopic fiber-optic Raman probe under fluoroscopic control during endoscopic retrograde cholangiopancreatography to measure Raman spectra of extrahepatic cholangiocarcinoma and healthy bile duct.
Sponsors
Palacky University
University Hospital Olomouc
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
20 patients with known extrahepatic cholangiocarcinoma, over 18 years of age
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* person older than 18 years, who has known extrahepatic cholangiocarcinoma and is indicated for ERCP
Exclusion criteria
* disagreement with the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The differences in Raman spectra of malignant biliary tissue compared to healthy biliary tissue | Perioperative/Periprocedural | During single ERCP procedure, we take 20 measurements of the Raman spectra (10 from malignant biliary tissue and 10 from healthy biliary tissue) that each tissue emits after interaction with the laser light. We are interested in the specific difference in the spectra of each tissue, which will be shown as a two-dimensional curve. The differences in the spectra of each tissue will be reflected by a change in the shape of the curve. |
Countries
Czechia
Contacts
Primary ContactPeter Slodička, M.D.
Backup ContactVáclav Ranc, Assoc. Prof.
Outcome results
None listed